What We're Reading: Page 252
Industry reads hand-picked by our editors
Sep 20, 2018
-
Bloomberg
Gilead faces doubts on Wall Street a year after $12 billion deal
-
Vox
What is Tilray? Why the Canadian cannabis company is worth more than American Airlines
-
Stat
In the battle for life sciences companies, one state shows up behind enemy lines
-
Kaiser Health News
Despite red flags at surgery centers, overseers award gold seals
Sep 19, 2018
-
ProPublica
Black Patients Miss Out On Promising Cancer Drugs
-
Reuters
AstraZeneca plots China robot offensive to counter price cuts
-
The New York Times
Why Your DNA Is Still Uncharted Territory
-
Evaluate
Novartis nears gene therapy confirmation
Sep 18, 2018
-
The Wall Street Journal
Trump promised a rush of repatriated cash, but company responses are modest
-
Reuters
Novartis links bonuses to ethics in bid to rebuild reputation
-
The New York Times
A Nobel laureate asks what makes a ‘disordered mind’
Sep 17, 2018
-
The Wall Street Journal
The Worst Is Over for Generic-Drug Stocks
-
The New York Times
For elderly women with breast cancer, surgery may not be the best option
-
Associated Press
Few safeguards for foster kids on psych drugs
Sep 14, 2018
-
The New York Times
Top Sloan Kettering Cancer Doctor Resigns After Failing to Disclose Industry Ties
-
Albany Times Union
Regeneron plans to add 1,500 in East Greenbush
-
Reuters
Roche steps up efficiency drive to take sting out of biosimilars
-
Kaiser Health News
Unwitting Patients, Copycat Comments Play Hidden Role In Federal Rule-Making
Previous
